Illumina (ILMN) reported $1.08 billion in revenue for the quarter ended September 2024, representing a year-over-year decline of 3.5%. EPS of $1.14 for the same period compares to $0.33 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $1.07 billion, representing a surprise of +0.48%. The company delivered an EPS surprise of +31.03%, with the consensus EPS estimate being $0.87.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Illumina performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenue- Core Illumina: $1.08 billion versus $1.08 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -2.4% change.

• Revenue- Microarrays- Consumables: $66 million compared to the $77.72 million average estimate based on two analysts. The reported number represents a change of -7% year over year.

• Revenue- Microarrays- Instruments: $3 million compared to the $3.65 million average estimate based on two analysts. The reported number represents a change of 0% year over year.

• Revenue- Microarrays- Total: $85 million compared to the $81.37 million average estimate based on two analysts. The reported number represents a change of -5.6% year over year.

• Revenue- Sequencing- Consumables: $741 million versus the two-analyst average estimate of $725.35 million. The reported number represents a year-over-year change of +6.6%.

• Revenue- Service and other revenue: $166 million versus $167.46 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -6.7% change.

• Revenue by Source- Total product revenue- Sequencing: $995 million versus $832.87 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -2.1% change.

• Revenues- Core Illumina- Total product revenue: $914 million versus the two-analyst average estimate of $911.15 million.

• Revenues- Core Illumina- Service and other revenue: $166 million compared to the $168.90 million average estimate based on two analysts.

• Revenue- Product revenue: $914 million versus the two-analyst average estimate of $914.24 million. The reported number represents a year-over-year change of -2.9%.

• Revenue- Sequencing- Instruments: $104 million versus the two-analyst average estimate of $107.52 million. The reported number represents a year-over-year change of -41.9%.